By: Dr. Gerardo Brunstein Diez Pérez
DE LA DISFUNCIÓN DIASTÓLICA A LA INSUFICIENCIA CARDIACA EVALUACIÓN DE LA PROGRESIÓN
By: Prof. Dr. Masao Sano, MD, FACC
A New Alternative for the Treatment of Heart Failure: Left Atrial to Coronary Sinus Shunt with the APTURE Device
ALT FLOW device for left atrial to coronary sinus shunting in symptomatic heart failure patients. In the treatment of heart failure (HF), significant improvement in patient quality of life and prognosis has been achieved through appropriate medical treatment and, in some cases, the use of devices. However, in certain cases, satisfactory clinical improvement cannot be...
A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip
Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone. However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the...
ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction
The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2...
AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure
Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction. These findings were presented during the scientific sessions at AHA 2020 and published simultaneously in JACC. EMPATROPISM outcomes are on the same line as other studies using sodium glucose 2 cotransporter inhibitors (SGLT2) which showed...
ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR
After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation therapy (DAPT). This study presented at ESC 2020, simultaneously published in NEJM, seems to go against the latest “fashion” (P2Y12 inhibitor monotherapy) and randomized patients to ASA monotherapy vs. DAPT with clopidogrel for 3 months. Unlike with the...
AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups
SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status. Dapagliflozin was originally developed for the treatment of type 2 diabetes. However, it has had a positive impact on various types of patients with chronic heart failure and reduced ejection fraction, including those without diabetes. This information is derived from...
AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure
Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and clinical events, according to the PIONEER-HF study presented at the American Heart Association (AHA) Congress Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). The study...
New Cardiac Failure Diagnoses after COVID-19 Infection
This is the largest study on new signs and symptoms of cardiac failure in patients after COVID-19. Even though low in prevalence, its occurrence in healthy patients with no prior risk factors is worrying. The potential for SARS-CoV 2 to directly affect the heart has been studied since the pandemic onset. These studies have shown...
- 1
- 2